Why Polynucleotides are Replacing Traditional Fillers in Medspas

We are seeing a definitive shift in patient preferences as polynucleotides move from a niche European import to a staple in our clinical protocols. Unlike traditional hyaluronic acid fillers that primarily provide mechanical volume through water retention, these salmon DNA-derived injectables function as true biostimulators. We find that by utilizing filtered, highly purified DNA fragments, we can trigger fibroblast proliferation and collagen synthesis at a cellular level without the risk of the puffy, overfilled look often associated with excessive cross-linked gels. From an operational standpoint, we are positioning these treatments for the periorbital area where thin skin makes traditional fillers risky due to the Tyndall effect. We believe the longevity of results and the regenerative nature of polynucleotides offer a more sustainable revenue model than temporary volume replacement, as patients prioritize long-term skin quality over immediate, artificial structural changes. Integrating this technology requires specific injector training on intradermal delivery techniques to maximize the regenerative signal.